FDA-label review · Updated July 2026
VIZZ Eye Drops for Presbyopia
A plain-language overview of aceclidine ophthalmic solution 1.44%, with a direct link to current FDA prescribing information.
Educational only. This page does not recommend VIZZ or determine candidacy. Use the current label and an eye-care professional's examination.
Label facts
- Active ingredient: aceclidine ophthalmic solution 1.44%
- Initial U.S. approval: July 2025
- Dosing overview: The label describes one drop in each eye followed by a second drop in each eye two minutes later, once daily.
Open the current FDA prescribing information for VIZZ →
What the medicine does—and does not do
VIZZ is approved to treat presbyopia in adults. Like other miotic presbyopia drops, it creates a pinhole effect through pupil constriction. It does not restore flexibility to the eye's lens or reverse the underlying age-related lens change.
Warnings to review
Read the product-specific label for blurred, dim, or dark vision warnings; retinal tear or detachment warnings; inflammation precautions; contact-lens instructions; interactions; and adverse reactions. Do not drive or operate machinery when vision is unclear. Seek urgent medical care for sudden flashing lights, floaters, or vision loss.
Read the FDA label warning overview →
Avoid cross-trial rankings
Percentages from separate product trials should not be compared as though the products were tested head to head. Trial populations, dosing, comparators, lighting, time points, and endpoints may differ.
Explore guided visual-skills practice
Get Visionary offers adaptive exercises for detail, contrast, recognition, and visual speed. It is a wellness app—not a medication, medical device, or substitute for professional eye care.
Explore Get Visionary